Enhancing Limb Salvage by Non-Mobilized Peripheral Blood Angiogenic Cell Precursors Therapy in Patients with Critical Limb Ischemia†


†ClinicalTrials.gov ID: NCT00523731
* Vascular Surgery Unit, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
** Theravitae Ltd. Nes Ziona, Israel
*** Ben-Gurion University, Beer Sheva, Israel

Background: Stem cell therapy has been proposed to enhance the salvage of critically ischemic limbs. Objective: Assess the efficacy and safety of the implantation of non-mobilized peripheral blood angiogenic cell precursors (NMPB-ACPs) in patients with critical limb ischemia (CLI) who were poor candidates for standard revascularization treatment options.

Material and Method: Six patients with CLI due to the infrapopliteal artery occlusive disease were included in the present study. Intramuscular injections of NMPB-ACPs were administered in the ischemic limbs. The efficacy was evaluated by clinical outcomes, ankle brachial index, toe brachial index, and computerized tomographic angiography.

Results: There was no evidence of local or systemic complication related to the procedure. Five patients (83.3%) had clinically significant improvement of adequate circulation at the distal limb for the complete healing. Four of them had complete healing of ischemic ulcers and stumps of toe amputation. However, one patient with adequate granulation tissue at the stump of the left first toe amputation subsequently suffered from severe foot infection originating from the other toes and eventually underwent below knee amputation. There was no improvement of circulation at the distal limb after the administration of NMPB-ACPs in one patient (16.7%) who eventually underwent major amputation.

Conclusion: The preliminary result of NMPB-ACPs therapy may be safe and provide benefits in the improvement of circulation in patients with CLI. A larger controlled trial is required to ascertain these preliminary results.

Keywords: Arterial occlusive diseases, Critical illness, Ischemia, Lower extremity, Peripheral blood stem cell transplantation, Stem cells

J Med Assoc Thai 2009; 92 (3): 320-7
Full text. e-Journal: http://www.mat.or.th/journal

Critical limb Ischemia (CLI) is a serious problem of peripheral arterial occlusive disease due to the high tendency of major limb loss(1-3). The comorbidities of ischemic heart disease and cerebrovascular disease are commonly associated with this problem; resulting in high mortality and disability during the management(4-6). The primary treatments including arterial bypass surgery, intervention and endovascular procedures may not succeed in many patients due to their poor distal artery run off and extensive calcification in lower extremity arteries. Major amputation therefore
is inevitable in this situation\(^{7,8}\). Autotransplantation of bone marrow cell\(^{9,10}\) and granulocyte colony stimulating factor-mobilized peripheral blood mononuclear cell demonstrated the improvement of circulation in critically ischemic limbs\(^{11-15}\).

The authors recently reported the generation of enriched population of angiogenic progenitor cells from human peripheral blood without the stimulation of bone marrow by granulocyte colony stimulating factor (G-CSF), called non-mobilized peripheral blood angiogenic cell precursors (NMPB-ACPs)\(^{16}\). Bone marrow (BM) -derived stem/progenitor cells can be obtained by direct aspiration from the bone marrow, a procedure that entails pain and discomfort and requires the use of anesthesia. An alternative method of obtaining cells from the BM by pre-treating the patient with G-CSF to induce migration of BM cells to the peripheral blood (mobilized peripheral blood) might result in increased blood viscosity, metabolic demand, and platelet counts\(^{17-20}\). To circumvent the risks and discomfort caused by either method. The authors opted to use cells harvested from non-mobilized peripheral blood as the raw material for ACP generation.

These cells simultaneously expressed Ulex-lectin and uptake of acetylated low density lipoprotein (Ac-LDL) as well as markers CD34, CD133, vascular endothelial growth factor (VEGF) receptor 2 (also known as kinase domain region [KDR], Tie-2, CD144, von Willebrand factor [vWF], and CD31. They also secreted interleukine-8 (IL-8), VEGF, and angiogenin, and formed tube-like structures in vitro\(^{10}\). However, the clinical potential of these cells is yet to be determined.

The objective of the present pilot study was to assess the safety and efficacy of intra-muscular injections of NMPB-ACPs in patients with critical limb ischemia who were unresponsive to intensive medical therapy and unsuitable for revascularization procedure.

**Material and Method**

A pilot non-randomized, open-label study was carried out in six patients with the permission of the Ethics Committee, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. The patients under the age of 85 years old with the symptoms of critical limb ischemia (Fontaine stage III and IV)\(^1\) such as ischemic rest pain, ischemic non-healed ulcer and digital gangrene together with hemodynamic assessment indicating limb threatening ischemia such as ankle brachial index (ABI) below 0.4, or toe brachial index (TBI) below 0.24 were enrolled in the present study\(^{21-23}\). The computerized tomographic angiography (CTA) also demonstrated the site of arterial occlusion at the infrapopliteal level with poor distal artery run off.

The patients suffering from stroke, valvular heart diseases, cardiomyopathy, malignant diseases, chronic infectious diseases such as AIDS and hepatitis as well as those receiving blood transfusion within 4 weeks preceding the recruitment were excluded from the present study.

**Cell Culture: Two hundred and fifty milliliters of blood were taken from the peripheral vein of the patients in the present study, stored in a container at the temperature of 2°C-8°C and transported to the manufacturing facility in Israel. The isolation and incubation of autologous ACPs were performed by Theravita Co Ltd (Israel). Low-density synergetic cell populations (SCP) were isolated as described previously\(^{16}\). To generate NMPB-ACPs, SCPs were cultured at a concentration of 1.5-3.0 x 10^6 cells/ml in X-vivo 15 serum-free medium (Cambrex, East Rutherford, NJ) supplemented with 10% autologous human serum, 1-10 ng/ml VEGF(R&D Systems, Minneapolis, MN) and 5 IU/ml heparin (Kamada, Beit-Kama, Israel). The process of obtaining the stem cell was performed for five days.

Flow Cytometry: Prior to implantation, the NMPB-ACPs were harvested for analysis. The cells were incubated in the dark, on ice, for 30 minutes, with specific fluorochrome-conjugated CD34-APC (BD Biosciences, San Jose, CA) and CD31-PE (eBioscience, San Diego, CA), or with isotype-matched non-specific controls. To assess the cells potential to uptake Ac-LDL, NMPB-ACPs were loaded with 0.8 mg/ml DiO-Ac-LDL (BTI, Stoughton, MA,USA) for 15 minutes at 37°C. Exclusion of dead cells from the final analysis was performed using 7-amino actinomycin D ([7-AAD], eBioscience) staining. Cell suspension triplicates of 500,000 cells each was stained, assessed by fluorescence-activated cell-sorting ([FACS], FACSCalibur, Becton Dickinson) and analyzed by Cell Quest Pro software (Becton Dickinson). For each replication, at least 30,000 cells were acquired. The percentage of each marker was determined in each test tube. In addition, the mean and% coefficient of variance (%CV) were calculated for each marker. The results were reported as mean ± standard error (SE) of the percentage of stained cells. The number of stained cells was calculated by multiplying the number of harvested cells with the staining percentages obtained using the FACS.

ELISA assay for the detection of Interleukine-8 secretion: Samples of culture medium were
collected from cells on the harvesting day. Secretion of the chemokines Interleukine-8 (IL-8), also known as the chemokine CXCL8) to the culture medium, was tested using commercial ELISA Kit (R&D systems Inc. MN, USA). Triplicates of standard curve consisting of seven dilutions and tested samples, each at four dilutions, were analyzed. The intensity of the color proportional to the IL-8 amount was measured using a microplate reader (Multiskan EX) and Ascent Software for Multiskan (Thermo Fisher Scientific, Inc, MA, USA). IL-8 concentration was determined relative to the standard curve samples. The final concentration was expressed as IL-8 secreted per total cell dose.

The injection procedure was done in a prone position with local anesthesia, sedation together with the monitoring of vital signs, electrocardiography and oxygen saturation. The injection was performed into calf muscles at 30 sites with one milliliter of stem cell suspension for each site, which was 1.5 centimeter apart. After the procedure, the patient was observed in hospital for monitoring hemodynamic status and systemic adverse events. Laboratory studies of hematology, kidney, and liver function including the level of serum myoglobin were completely assessed before and after the procedure. The hemodynamic assessment of limb ischemia was performed by ABI and TBI at 1 and 3 months after the treatment. The increase of 0.15 of segmental pressure index was considered significant improvement (24,25). The CTA was repeated 3 months post procedure. The assessment of the degree of collateral circulation and the evidence of recanalization of the distal artery in CTA (26) was performed by the radiologist who was blinded to the present study. The primary end points of the clinical efficacy assessment were absolute disappearance of rest pain and complete healing of ischemic ulcer and stump of digital amputation. The follow up period was at least 3 months post treatment.

Results
Six male patients with the mean age of 65.5 ± 14.7 (range 38.6-83.8) years were enrolled in the present study. The clinical presentations were digital gangrene in four patients and ischemic ulcer in three patients (one patient had both gangrene and ulcer). One patient also had limited intermittent claudication with 100 meter maximal walking distance (Table 1). All six patients in the present study were classified as Fontaine stage IV (1). The average duration of clinical presentations was 5.0 ± 1.8 (range3.1-7.1) months. The risk factors of atherosclerosis detected in this group were diabetes mellitus in four (66.7%) patients, hypertension in three (50%) patients, heavy smoking in three (50%) patients and hypercholesterolemia in one (16.7%) patient. Ischemic heart disease was found in three (50%) patients and two (33.3%) of them had previous coronary bypass surgery. Prior to the present study, one patient had below the knee amputation on the contralateral limb 5 years ago and the fifth toe amputation on the affected limb one year ago. All six patients had TBI below 0.24 and two patients had ABI at and below 0.4 (Table 1). CTA of the lower extremities also demonstrated poor distal artery run off which caused the patients to be unsuitable for revascularization. Prior to the enrollment in the present study, ischemic ulcer and distal gangrene in these patients were treated for at least two months without any improvement. Toe amputations were planned without the promisingly complete healing process. Below the knee amputations were expected in all of them.

There was no change of hemodynamic status after taking 250 milliliters of peripheral blood from the patients in the process of NMPB-ACPs production. The harvested cells, 54.5 x 10⁶ ± 10.2 x 10⁶ (mean ± SE, n = 6) in number, were administered by thirty intramuscular injections into the gastrocnemius muscle of the ischemic limb. The NMPB-ACPs were harvested after culturing exhibited high viability levels of 97.7% ± 0.6% (mean ± SE, n = 6). Flow cytometry (FACS) assessment showed the expression of the stem cell markers CD34 in 19.0% ± 2.4% (mean ± SE, n = 6) of the cells, concomitant expression of CD31, uptake of Ac-LDL in 33.2% ± 7.4% (mean ± SE, n = 6) of the cells and IL-8 ng/dose in 189.7% ± 158.0% (mean ± SE, n = 6) of the cells (Fig. 1).

In the immediate follow-up after the intramuscular injection of NMPB-ACPs, five patients were hemodynamically stable. One patient developed the symptoms of dyspnea during the night. These symptoms were caused by fluid overload with immediate response to diuretic therapy. Elevated cardiac enzymes were detected even though the patient had no symptom of angina. He refused to undergo the invasive evaluation of ischemic heart disease. There were no abnormalities in the laboratory tests of hematology, kidney and liver function including the level of serum myoglobin. In the present study, five patients (83.3%) had clinically significant improvement of circulation at the distal limb adequate for the complete healing (Table 1). Two of them had the complete healing of ischemic ulcer. Another two with digital gangrene underwent toe amputation with
Table 1. Clinical outcomes, ankle brachial index (ABI), toe brachial index (TBI) and computerized tomographic angiography (CTA) at baseline and follow-up

<table>
<thead>
<tr>
<th>No.</th>
<th>Clinical outcomes</th>
<th>ABI</th>
<th>TBI</th>
<th>CTA at 3 month follow-up visit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Clinical outcomes</td>
<td>Baseline</td>
<td>1 month</td>
<td>3 months</td>
</tr>
<tr>
<td>1</td>
<td>Non-healed ischemic ulcer at left 1st toe</td>
<td>Complete ulcer healing</td>
<td>0.77</td>
<td>0.92*</td>
</tr>
<tr>
<td>2</td>
<td>Rest pain and digital gangrene at right 1st toe</td>
<td>Complete healing of toe amputation</td>
<td>1.08</td>
<td>1.09</td>
</tr>
<tr>
<td>3</td>
<td>Digital gangrene at right 2nd toe</td>
<td>Complete healing of toe amputation</td>
<td>0.70</td>
<td>0.70</td>
</tr>
<tr>
<td>4</td>
<td>Non-healed Ischemic ulcer at left 1st toe and limited intermittent claudication (100 meters)</td>
<td>Complete ulcer healing Improvement of intermittent claudication</td>
<td>0.55</td>
<td>0.80*</td>
</tr>
<tr>
<td>5</td>
<td>Digital gangrene at left 1st toe</td>
<td>Significant improvement of granulation tissue at base of toe stump but underwent BKA after infection due to poor compliance</td>
<td>0.40</td>
<td>0.40</td>
</tr>
<tr>
<td>6</td>
<td>Ischemic ulcer and digital gangrene at left 5th toe</td>
<td>No improvement which might relate to congestive heart failure and finally underwent BKA</td>
<td>0.26</td>
<td>0.31</td>
</tr>
</tbody>
</table>

* The increase of 0.15 of segmental pressure index was considered significant improvement
** No flow; NP: not performed, BKA: below knee amputation
the complete healing of the stump. Among these patients, one also had an improvement of intermittent claudication from 100 to 400 meters within three months and no symptom after six months. One patient had significant improvement of healing with the adequate granulation tissue at the base of the first toe stump (Fig. 2). Due to poor compliance and severe foot infection originated from the second and third toes with septicemia, this patient subsequently underwent below the knee amputation. On the contrary, one patient (16.7%) had no improvement after the administration of NMPB-ACPs. The ischemic process of the affected limb was progressively worse, requiring below the knee amputation (Table 1). All patients survived the 6-month follow up period.

In hemodynamic assessment during the 3-month follow up, two patients had an improvement in both ABI and TBI, one patient improved only in ABI and another only in TBI. However, two patients had no improvement in ABI or TBI. The CTA at three months post treatment demonstrated the recanalization of distal artery in three patients and the increase of collateral circulation in two of them (Table 1). Fig. 3 demonstrated the increase of collateral circulation and recanalization of the distal artery after the administration of NMPB-ACPs.

Discussion

Despite technical advance in intervention and surgical revascularization procedures, a substantial number of patients with peripheral arterial occlusive disease and critical limb ischemia remain in whom major amputation has to be considered the only final option (7). However, there were several studies of autotransplantation of bone marrow origin cells (9,10) and G-CSF mobilized peripheral blood mononuclear cells in patients with critical limb ischemia demonstrating the improvement of ischemic status (11-15). Subsequently, these therapeutic modalities may enhance the opportunity of limb salvage in those patients. Due to the harmful effect of G-CSF to cardiac patients (20), the use of peripheral blood as raw material to provide angiogenic cell precursors without the stimulation of bone marrow by injection of G-CSF is simpler, safer, and more suitable for the elderly patient with high-risk comorbidities.

The present study illustrated that direct intramuscular injection of NMPB-ACPs had improved the distal circulation in five patients (83.3%) with a critically ischemic limb by achieving complete ulcer or toe stump healing in four (66.7%) patients and
providing the adequate granulation tissue at the base
of first toe stump in one (16.7%) patient (Fig. 2). These
results indicated the efficiency of NMPB-ACPs in
critical limb ischemia. Due to poor compliance and
subsequently extensive foot infection, below the knee
amputation was inevitable in the latter patient result-
ing in the incomplete assessment of the healing
process. The successful outcome was supported by
the improvement of ABI and/or TBI in four patients
who had complete ulcer and/or toe stump healing and
the evidence of CTA improvement in three patients
with increased collateral circulation and/or the
recanalization in the distal artery. However, there was
no improvement of distal circulation in one patient
(16.7%) who had dyspnea due to fluid overload after
the injection. This clinical result was also confirmed by
no change of ABI and TBI and no change in the degree
of collateral circulation and recanalization in CTA.

The compromised cardiac status may play a role of the
proliferation of injected progenitor cells. In addition,
this patient had the most severe ischemia in this group
suffering from both ischemic ulcer and digital gangrene.
The ABI and TBI of this patient were also the lowest in
this group. It is worth identifying the level of ischemia
at which NMPB-ACPs is unable to improve the circula-
tion. There was no abnormality in the laboratory study
of hematology, kidney, and liver function as well as
the level of serum myoglobin in all patients after the
treatment, indicating that the injection of NMPB-ACPs
was safe for patients with critical limb ischemia.

In conclusion, intramuscular injection of
NMPB-ACPs may provide safety, and feasibility for
the enhancement of limb salvage in patients with
critical ischemic limb. The real efficacy of NMPB-ACPs
for ischemic limb requires randomized control trials in
a larger series of such patients.

Acknowledgments
The authors thank Professor V. Thamlikitkul
for his advice and assistance, Associates Professor
P. Vessakosol (PhD) and S. Tunpornpituk in the
preparation of this manuscript.

References
1. Norgren L, Hiatt WR, Dormandy JA, Nehler
MR, Harris KA, Fowkes FG, et al. Inter-society
consensus for the management of peripheral
2. Critical limb ischaemia: management and outcome.
Report of a national survey. The Vascular Surgical
Society of Great Britain and Ireland. Eur J Vasc
3. Mutirangura P, Ruangsetakit C, Wongwanit C,
Sermsathanasawadi N, Chinsakchai K. Athero-
sclerosis obliterans of the lower extremities in Thai
4. Hertzer NR, Beven EG, Young JR, O’Hara PJ,
Ruschhaupt WF 3rd, Graor RA, et al. Coronary
artery disease in peripheral vascular patients. A
classification of 1000 coronary angiograms and
199: 223-33.
5. Gentile AT, Taylor LM Jr, Moneta GL, Porter JM.
Prevalence of asymptomatic carotid stenosis in
patients undergoing infrainguinal bypass surgery.
6. Turnipseed WD, Berkoff HA, Belzer FO. Post-
operative stroke in cardiac and peripheral vascular
revascularization and limb salvage always the
best treatment for critical limb ischemia? J Vasc
8. Nehler MR, Wolford H. Natural history and
nonoperative treatment of chronic lower extremity

Fig. 3 Demonstration of the increase of collateral circula-
tion and recanalization of the distal artery before
and after the administration of NMPB-ACPs in
the second patient (Arrow: recanalisation of right
peroneal artery)
การฉีดเซลล์ต้นแบบของหลอดเลือดในผู้ป่วยที่มีภาวะขาดเลือดในขั้นวิกฤตเพื่อการเพิ่มประสิทธิภาพในการเก็บรักษา

ประมวล มุทิรางกูร, เฉนียน เรืองเศรษฐกิจ, ชุมพล ว่องวานิช, คามิน ชินศักดิ์ชัย, Yael Porat, Adina Belleli, David Czeiger

ภูมิหลัง: เพื่อศึกษาประสิทธิภาพและความปลอดภัยของการใช้เซลล์ต้นแบบของหลอดเลือดที่สกัดมาจากเลือดของผู้ป่วยในการรักษาผู้ป่วยที่มีภาวะขาดเลือดขั้นวิกฤต

วัสดุและวิธีการ: การศึกษานี้กระทำในผู้ป่วย 6 รายที่มีภาวะขาดเลือดขั้นวิกฤตในข้อเท้าหรือนิ้วเท้า ขาดเลือดขั้นวิกฤตต่ำแใหม่ไม่สามารถรักษาได้โดยการผ่าตัดหรือการขยายเลือดแดงที่มีการตีบแคบผ่านทางสายสวนได้ ภาวะขาดเลือดขั้นวิกฤตนี้ได้รับการตรวจยืนยันโดยการวัดค่าดีนิยมและวัดค่าดีนิยม Dcn พร้อมทั้งการตรวจสภาพหลอดเลือดแดงด้วยเครื่องเอกซเรย์คอมพิวเตอร์ 3 มิติ การรักษากระทำโดยการฉีดเซลล์ต้นแบบของหลอดเลือดเข้าไปในกล้ามเนื้อน่องของขาที่มีขาดเลือดแดง แกนหลอดแบบของหลอดเลือดที่สกัดมาจากเลือดของผู้ป่วยโดยไม่มีการใช้สารกระตุ้นไขกระดูกเพื่อสร้างเซลล์ต้นแบบ

ผลการศึกษา: พบว่าผู้ป่วยทั้ง 6 รายไม่มีภาวะแทรกซ้อนเฉพาะที่และทั่วร่างกายใด ๆ ที่เกี่ยวข้องกับการใช้เซลล์ต้นแบบของหลอดเลือด ผู้ป่วยที่ 5 ราย (ร้อยละ 83.3) มีลักษณะอาการต่างๆที่มีการเพิ่มเลือดประจำการที่ได้รับการรักษาอย่างรวดเร็วที่สูงถึง 100 มิลลิลิตรในหนึ่งนั้น ไม่รับยาปฏิชีวนะหรือยาขนาดเล็กหรือยาขนาดเล็กที่มีการติดเชื้อหรือสารกระตุ้นไขกระดูก ตัวอย่างเช่นการรักษาภาวะขาดเลือดในข้อเท้าและนิ้วเท้า ผู้ป่วยคนที่ 1 รายมีการหายของแผลต่างๆที่มีการหายซึ่งไม่สามารถรักษาได้โดยการฟื้นฟูอย่างปกติ อย่างไรก็ตามผู้ป่วยที่มีภาวะขาดเลือดขั้นวิกฤตอย่างน้อย 1 ราย (ร้อยละ 17.7) พบว่ามีภาวะแทรกซ้อนเฉพาะที่มีการติดเชื้อหรืออาการต่างๆที่เกี่ยวข้องกับภาวะขาดเลือดขั้นวิกฤต

สรุป: การศึกษาโดยใช้เซลล์ต้นแบบของหลอดเลือดที่สกัดมาจากเลือดของผู้ป่วยที่มีภาวะขาดเลือดขั้นวิกฤตไม่ได้มีความปลอดภัย และมีผลส่งผลต่อการเพิ่มเลือดและเก็บรักษา.lenไม่สามารถรักษาได้โดยวิธีการฟื้นฟูของผู้ป่วยในขั้นต่อไป